Pay in 4 interest-free payments of $5.48 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Tirzepatide (Mounjaro) is a dual GIP and GLP-1 receptor agonist licensed in the UK for type 2 diabetes and weight management in adults with obesity or overweight with comorbidities
*Correspondence: Youxin Chen, [email protected] These authors have contributed equally to this work and share first authorship Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Several FDA-approval drugs will be discussed, including liraglutide, semaglutide, tirzepatide, orlistat, and combinations like phentermine/topiramate and bupropion/naltrexone, noting their effectiveness in obesity management [34, 35] (Table 1)
Weight loss during this period is typically modest, primarily due to reduced caloric intake
The client sees less visible change per session than the treatment should produce
I lost almost 50 pounds
